When:
Thursday, April 12, 2018
1:30 PM - 2:30 PM CT
Where: Robert H Lurie Medical Research Center, Baldwin Auditorium, 303 E. Superior, Chicago, IL 60611 map it
Audience: Faculty/Staff - Post Docs/Docs - Graduate Students
Contact:
Stephen D. Miller, PhD
(312) 503-7674
Group: Department of Microbiology-Immunology Seminars/Events
Category: Lectures & Meetings
Department of Microbiology-Immunology Seminar Series
“Resistance to Chimeric Antigen Receptor T Cells”
Marco Ruella, MD / University of Pennsylvania
Description:
Anti-CD19 chimeric antigen receptor T cells (CART19) are now an FDA-approved drug for relapsed leukemia and lymphoma. The approval by the FDA of the first adoptive T cell therapy, the UPenn/Novartis CART19 (CTL019), represents a milestone for cancer treatment and paves the way to the use of the CART technology in other cancers and in combination with other agents. Intense scientific research is currently ongoing with the goal of improving safety, increasing response rates and avoiding relapses. In his talk Dr. Ruella will present his recent studies on a new resistance mechanism to CART immunotherapy and present strategies to overcome resistance and extend CART therapy to other hematologic cancers.